Comparison of Secukinumab and Ixekizumab in psoriasis: a real‐life cohort study on the efficacy and drug survival of 445 patients

2021 ◽  
Author(s):  
C Cariti ◽  
P Dapavo ◽  
L Mastorino ◽  
M Ortoncelli ◽  
N Siliquini ◽  
...  
Keyword(s):  
Cohort Study ◽  
Real Life ◽  
Drug Survival

scholarly journals Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Vaccines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 372
Author(s):  
Léna Royston ◽  
Eva Royston ◽  
Stavroula Masouridi-Levrat ◽  
Nathalie Vernaz ◽  
Yves Chalandon ◽  
...  
Keyword(s):  
Renal Function ◽  
Cohort Study ◽  
High Risk ◽  
Real Life ◽  
Primary Prophylaxis ◽  
Hematopoietic Cell ◽  
P Value ◽  
Cell Transplant ◽  
Matched Cohort ◽  
Matched Cohort Study

Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study, comparing consecutive high-risk allogeneic HCT recipients (cases) receiving primary prophylaxis with letermovir and untreated matched historical controls, during a study period of 180 days. The primary outcome was the incidence of clinically significant (cs) CMV infection. Secondary outcomes included duration and costs of CMV-antiviral treatments, hospital resource utilization, hematology and laboratory parameters. Results: Letermovir prophylaxis decreased csCMV infection incidence from 82.7% (controls) to 34.5% (cases; p-value < 0.0001). Controls were more likely to have >1 episode of csCMV infection (59.6%) compared to cases (11.5%; p-value < 0.0001). Letermovir was associated with: shorter overall CMV-associated treatment duration (49 days vs. 77.8 days; p-value: 0.02) and a trend for lower costs of CMV-associated treatments ($4096 vs. $9736; p-value: 0.07) and reduced length of stay (44.8 days vs. 59.8 days; p-value: 0.16). Letermovir administration was associated with significantly shorter duration (27.3 days vs. 57.1 days; p-value: 0.008) and lower costs ($1089 vs. $2281; p-value: 0.008) of valganciclovir treatment. Compared to controls, higher platelet counts were observed in cases (138 G/L vs. 92 G/L; p-value: 0.03) and renal function was improved (94 mL/min/1.73 m2 vs. 74 mL/min/1.73 m2; p-value: 0.006). Conclusions: Primary anti-CMV letermovir prophylaxis decreased the incidence of csCMV infection and the administration of CMV-associated treatments and costs, particularly those associated with valganciclovir. An effect of letermovir on platelet reconstitution and renal function of csCMV post-HCT was observed and needs further investigation.

scholarly journals P600 Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S415-S416
Author(s):  
A Eberl ◽  
T Hallinen ◽  
C-G af Björkesten ◽  
M Heikkinen ◽  
E Hirsi ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Real Life ◽  
Observational Cohort Study ◽  
Observational Cohort

Mo1884 - Drug Survival of Vedolizumab-Treated Inflammatory Bowel Disease Patients in a Nationwide Observational Cohort Study: ICC Case Series

2018 ◽  
Vol 154 (6) ◽  
pp. S-838
Author(s):  
Vince Biemans ◽  
Christien Janneke Van Der Woude ◽  
Gerard Dijkstra ◽  
Andrea Van Der Meulen ◽  
Bas Oldenburg ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cohort Study ◽  
Bowel Disease ◽  
Case Series ◽  
Observational Cohort Study ◽  
Drug Survival ◽  
Observational Cohort ◽  
Inflammatory Bowel

scholarly journals P456 Drug survival of thiopurine–allopurinol combination therapy in a real-life population-based cohort

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S335-S335
Author(s):  
J E Kreijne ◽  
R C de Veer ◽  
N K de Boer ◽  
G Bouma ◽  
G Dijkstra ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Real Life ◽  
Population Based ◽  
Drug Survival
Sign in / Sign up

Export Citation Format

Share Document